Travere Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Travere Therapeutics is Eric Dube, benoemd in Jan2019, heeft een ambtstermijn van 5.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.57M, bestaande uit 10.5% salaris en 89.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.15% van de aandelen van het bedrijf, ter waarde $ 2.12M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 7.6 jaar.
Belangrijke informatie
Eric Dube
Algemeen directeur
US$7.6m
Totale compensatie
| Percentage CEO-salaris | 10.5% |
| Dienstverband CEO | 5.8yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 4.1yrs |
| Gemiddelde ambtstermijn bestuur | 7.6yrs |
Recente managementupdates
Recent updates
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry
Oct 31
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Oct 07Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Sep 30Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sep 10Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Aug 30Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now
May 02Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop
Apr 20Travere Therapeutics: Restructuring Away From Disaster
Jan 30Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jan 22Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too
Dec 18New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)
Aug 08Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Jun 09It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks
May 05Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 16Travere Therapeutics' FDA target action date for nephropathy treatment extended
Oct 13Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Oct 06Travere Therapeutics: Changes In The Risk-Reward Assessment
Sep 29Travere, CSL kidney disease drug sparsentan gets review in EU
Aug 22Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
Aug 04Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
Jul 14Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?
Jun 19Travere Therapeutics: Strong Sell, Ticking Time Bomb, We Are Passing
Apr 11Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?
Feb 07Travere Therapeutics: Tarpeyo's Approval Is Good News
Jan 31Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$349m |
| Jun 30 2024 | n/a | n/a | -US$383m |
| Mar 31 2024 | n/a | n/a | -US$416m |
| Dec 31 2023 | US$8m | US$796k | -US$376m |
| Sep 30 2023 | n/a | n/a | -US$373m |
| Jun 30 2023 | n/a | n/a | -US$368m |
| Mar 31 2023 | n/a | n/a | -US$352m |
| Dec 31 2022 | US$6m | US$747k | -US$331m |
| Sep 30 2022 | n/a | n/a | -US$297m |
| Jun 30 2022 | n/a | n/a | -US$249m |
| Mar 31 2022 | n/a | n/a | -US$202m |
| Dec 31 2021 | US$6m | US$708k | -US$217m |
| Sep 30 2021 | n/a | n/a | -US$250m |
| Jun 30 2021 | n/a | n/a | -US$237m |
| Mar 31 2021 | n/a | n/a | -US$224m |
| Dec 31 2020 | US$5m | US$661k | -US$169m |
| Sep 30 2020 | n/a | n/a | -US$78m |
| Jun 30 2020 | n/a | n/a | -US$92m |
| Mar 31 2020 | n/a | n/a | -US$105m |
| Dec 31 2019 | US$10m | US$618k | -US$146m |
Compensatie versus markt: De totale vergoeding ($USD 7.57M ) Eric } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.64M ).
Compensatie versus inkomsten: De vergoeding van Eric is gestegen terwijl het bedrijf verliesgevend is.
CEO
Eric Dube (51 yo)
5.8yrs
Tenure
US$7,574,959
Compensatie
Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.15% $ 2.1m | |
| Chief Financial Officer | 2.3yrs | US$1.97m | 0.096% $ 1.3m | |
| Senior VP | 7.8yrs | US$2.02m | 0.10% $ 1.4m | |
| Senior VP and Head of Research & Development | 7.8yrs | US$2.05m | 0.046% $ 625.5k | |
| Chief Commercial Officer | 5.1yrs | US$2.00m | 0.076% $ 1.0m | |
| SVP, Corporate Controller & Chief Accounting Officer | 3.2yrs | geen gegevens | 0.067% $ 914.0k | |
| Vice President of Corporate Communications & Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Human Resources | no data | geen gegevens | geen gegevens | |
| Chief Business Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Medical Officer | 2.8yrs | US$2.87m | 0.079% $ 1.1m | |
| Senior Vice President of Public Affairs | no data | geen gegevens | geen gegevens |
4.1yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TVTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 5.8yrs | US$7.57m | 0.15% $ 2.1m | |
| Independent Director | 7.7yrs | US$372.98k | 0.037% $ 507.4k | |
| Independent Chairman of the Board | 10.1yrs | US$392.98k | 0.065% $ 896.0k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 4.6yrs | US$372.36k | 0.029% $ 391.0k | |
| Independent Director | 8.4yrs | US$376.73k | 0.040% $ 544.7k | |
| Independent Director | 3.2yrs | US$365.48k | 0.025% $ 338.2k | |
| Independent Director | 9.7yrs | US$385.48k | 0.063% $ 860.9k | |
| Independent Director | 7.6yrs | US$367.98k | 0.037% $ 507.4k | |
| Independent Director | 10.1yrs | US$379.98k | 0.10% $ 1.4m | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.5yrs | US$369.86k | 0.030% $ 412.9k |
7.6yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TVTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.6 jaar).